PET-guided high-dose vitamin C synergised with 131I, 177Lu-DOTA-TATE, 177Lu-PSMA for advanced thyroid cancer, neuroendocrine tumours, and prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076126

Enrollment

Unknown

Registered

2023-09-25

Start date

2023-09-27

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced thyroid cancer, neuroendocrine tumours, and prostate cancer

Interventions

Experimental group:1) PET/CT examination: 18F-FDG, 18F-FAA PET/CT imaging 2) 131I, 177Lu-DOTA-TATE, 177Lu-PSMA internal irradiation routine treatment 3) Intravenous and/or intratumoral vitamin C inje

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age older than 18 years ? Locally advanced, metastatic or recurrent thyroid adenocarcinoma, neuroendocrine tumors, prostate cancer and other advanced malignant tumors that have failed pathologically confirmed conventional treatment or are unwilling to carry out conventional treatment, 18F-FAA PET/CT imaging positive, suitable for 131I, 177Lu-DOTA-TATE, 177Lu-PSMA and other nuclear internal radiation treatment ? At least 1 measurable lesion can be assessed by PET/CT evaluation. ? Expected survival is greater than 3 months ? Physical Condition ECOG score 0-2 points ? There are no serious abnormal blood system, heart, and lung function, and the blood system and terminal organs are well functioned(ANC = 1500 mm3 , platelets = 100,000/mm3 , hemoglobin = 9 g/dL, serum creatinine =1.8 mg/dL or creatinine clearance > 50 mL/min, bilirubin = 1.5 mg/dL, alanine aminotransferase (ALT), aspartate transaminase (AST) = 2.5 times the upper limit of normal

Exclusion criteria

Exclusion criteria: ? Glucose-6 phosphate dehydrogenase (G6PD) deficiency ? Oxalic acid kidney stones ? Patients with high iron load, hemochromatosis, or hemosiderosis ? Active heart disease and other serious uncontrolled conditions ? Pregnant or lactating

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Secondary

Measure	Time frame
Overall survival;progression free survival;security;	—

Countries

China

Contacts

Public ContactXiangsong Zhang

The First Affiliated Hospital of Sun Yat-Sen University

zhxiangs@mail.sysu.edu.cn+86 189 0223 3613

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 30, 2026